Cost-effectiveness analysis of adjuvant anastrozol in postmenopausal women with breast cancer;Estudo de custo-efetividade do anastrozol adjuvante no câncer de mama em mulheres pós-menopausa

Revista da Associacao Medica Brasileira

Volumn 55, Issue 5, 2009, Pages 535-540

  Sasse, Andre Deeke ^a   Sasse, Emma Chen ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Adjuvant breast Neoplasms; Aromatase inhibitors; Chemotherapy; Cost effectiveness evaluation; Markov chains; Tamoxifen

Indexed keywords

EID: 70450175380     PISSN: 01044230     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0104-42302009000500015     Document Type: Article

References (25)

1. Instituto Nacional do Câncer - INCA. Estimativa 2008: incidência de cancer no Brasil. 2008 [citado 01 set 2008]. Disponível em: http:www.inca.gov.br/estimativa 2006.
2. Fundação Oncocentro do Estado de São Paulo - FOSP. Banco de dados do Registro Hospitalar de Câncer. 2008 [citado 15 ago 2008]. Disponível em: http://www.fosp.saude.sp.gov.br.
3. Kapoor A, Vogel VG. Prognostic factors for breast cancer and their use in the clinical setting. Expert Rev Anticancer Ther. 2005;5(2):269-81.
4. Hochster HS. Capecitabine plus oxaliplatin vs infusional 5-fluorouracil plus oxaliplatin in the treatment of colorectal cancer. Con: Pumpin FU (or, avoiding that oral fixation). Clin Adv Hematol Oncol. 2005;3(5):405-6.
5. Rochefort H, Borgna JL. Differences between oestrogen receptor activation by oestrogen and antioestrogen. Nature. 1981;292(5820):257-9.
6. Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M. Effect of anas-trozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9(1):45-53.
7. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years adjuvant treatment for breast cancer. Lancet. 2005;365(9453):60-2.
8. Duffy SR, Distler W, Howell A, Cuzick J, Baum M. A lower incidence of gynecologic adverse events and interventions with anastrozole than with tamoxifen in the ATAC trial. Am J Obstet Gynecol. 2009;200(1):80 e1-7.
9. Colozza M, Califano R, Minenza E, Dinh P, Azambuja E. Aromatase inhibitors: a new reality for the adjuvant endocrine treatment of early-stage breast cancer in postmenopausal women. Mini Rev Med Chem. 2008;8(6):564-74.
10. Balducci L. Treating elderly patients with hormone sensitive breast cancer: what do the data show? Cancer Treat Rev. 2009;35(1):47-56.
11. Buzdar A, Howell A, Cuzick J, Wale C, Distler W, Hoctin-Boes G, et al. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol. 2006;7(8):633-43.
12. Mano M. The burden of scientific progress: growing inequalities in the delivery of cancer care. Acta Oncol. 2006;45(1):84-6.
13. Barros AJ, Bertoldi AD. Out-of-pocket health expenditurein a population covered by the Family Health Program in Brazil. Int J Epidemiol. 2008;37(4):758-65.
14. Mansel R, Locker G, Fallowfield L, Benedict A, Jones D. Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC (Arimidex, Tamoxifen alone or in combination) trial. Br J Cancer. 2007;97(2):152-61.
15. Moeremans K, Annemans L. Cost-effectiveness of anastrozole compared to tamoxifen in hormone receptor-positive early breast cancer. Analysis based on the ATAC trial. Int J Gynecol Cancer. 2006;16(Suppl 2):576-8.
16. Locker GY, Mansel R, Cella D, Dobrez D, Sorensen S, Gandhi SK. Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial. Breast Cancer Res Treat. 2007;106(2):229-38.
17. Rocchi A, Verma S. Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed- treatment analysis. Support Care Cancer. 2006;14(9):917-27.
18. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13(4):322-38.
19. Kamby C, Sengelov L. Pattern of dissemination and survival following isolated locoregional recurrence of breast cancer. A prospective study with more than 10 years of follow up. Breast Cancer Res Treat. 1997;45(2):181-92.
20. Anexo da Revista ABCFARMA - Lista de Preços. Fevereiro 2008. Ano 16, Edição 198.
21. Associação Médica Brasileira. Classificação Brasileira Hierarquizada de Procedimentos Médicos. Setembro 2008, 5a. edição. ISBN 85-89073-03-3.
22. Sorensen SV, Benedict A, Flood D, Revicki D, Brown R. Patient-rated utilities in postmenopausal early breast cancer (EBC): a cross-country comparison. Value Health. 2004;7(6):641-2.
23. Muennig P. Designing and conducting cost-effectiveness analyses in medicine and health care. 2002.
24. Meropol NJ, Schulman KA. Cost of cancer care: issues and implications. J Clin Oncol. 2007;25(2):180-6.
25. Rawlins M. Paying for modern cancer care--a global perspective. Lancet Oncol. 2007;8(9):749-51.